Argonaut Announces Management Change.Business Editors FOSTER CITY, Calif.--(BUSINESS WIRE)--April 1, 2002 Argonaut Technologies, Inc. (Nasdaq:AGNT AGNT Association for Global New Thought AGNT Agent Table ), today announced that John Supan has resigned as chief financial officer of the company to pursue other interests. Argonaut also announced that, effective immediately, Lissa Goldenstein, Argonaut's president and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. has been appointed acting chief financial officer. William Calkins continues as Argonaut's corporate controller. The company has begun a formal search for a chief financial officer. Lissa Goldenstein thanked Mr. Supan for his contributions to Argonaut. Ms. Goldenstein stated, "I greatly appreciate John's dedication to Argonaut's success. We are actively looking for Looking for In the context of general equities, this describing a buy interest in which a dealer is asked to offer stock, often involving a capital commitment. Antithesis of in touch with. his successor. In the meantime Adv. 1. in the meantime - during the intervening time; "meanwhile I will not think about the problem"; "meantime he was attentive to his other interests"; "in the meantime the police were notified" meantime, meanwhile , finance and accounting activities will be handled by myself, Bill Calkins and our capable staff as well as our accounting and finance consultants." Argonaut Technologies, Inc. Argonaut Technologies, Inc. is a leader in the development of innovative products that speed and simplify how chemists discover and test new chemical entities. Our products enable chemists to increase their productivity, reduce their operating costs operating costs npl → gastos mpl operacionales through automation and process simplification, achieve faster time-to-market for new products, and cost-effectively explore the increasing number of drug targets available for drug development. We provide solutions that are used in over 1,000 pharmaceutical, chemical and academic laboratories worldwide. Our instruments, software and consumables for parallel synthesis enable chemists to perform multiple experiments under a variety of conditions in a fraction of the time and cost of traditional methods. Forward Looking Statements Statements included in this press release that are not historical in nature may be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Examples of such forward-looking statements include, without limitation, statements regarding the ability of our products to enhance chemical development and statements regarding the ability to recruit and retain management. Any such forward-looking statements involve risks and uncertainties and reflect Argonaut's judgment as of the date of this release. These and other risk factors are discussed in Argonaut's Annual Report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. for the year ended December 31, 2001 filed on April 1, 2002, and its other filings with the Securities and Exchange Commission. Argonaut disclaims any intent or obligation to update these forward-looking statements. The Company claims the protection of the Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion